Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences ConferenceGlobeNewsWire • 05/09/23
Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023GlobeNewsWire • 05/02/23
Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual MeetingGlobeNewsWire • 04/27/23
Clearside Biomedical's Suprachoroidal Injection Platform to be Featured at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual MeetingGlobeNewsWire • 04/19/23
Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMDGlobeNewsWire • 04/18/23
Clearside Biomedical to Participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/12/23
Clearside Biomedical Enhances Scientific Advisory Board with the Appointment of Two Distinguished Retinal PhysiciansGlobeNewsWire • 04/05/23
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/10/23
Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/09/23
Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023GlobeNewsWire • 02/23/23
Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual MeetingsGlobeNewsWire • 02/21/23
Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023GlobeNewsWire • 02/07/23
Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMDGlobeNewsWire • 02/02/23
Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022GlobeNewsWire • 11/22/22
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare ConferenceGlobeNewsWire • 11/10/22
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/09/22
Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/09/22
Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD PatientsGlobeNewsWire • 11/09/22
Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/08/22
Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022GlobeNewsWire • 11/02/22
Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical's Proprietary Suprachoroidal Space PlatformGlobeNewsWire • 10/04/22
Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual MeetingGlobeNewsWire • 09/27/22